Copyright Reports & Markets. All rights reserved.

Global Pleurodynia Treatment Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Pleurodynia Treatment Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Anti-Inflammatory Drugs
    • 1.3.3 Analgesics
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Pleurodynia Treatment Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Other
  • 1.5 Global Pleurodynia Treatment Market Size & Forecast
    • 1.5.1 Global Pleurodynia Treatment Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Pleurodynia Treatment Sales Quantity (2021-2032)
    • 1.5.3 Global Pleurodynia Treatment Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche Holding AG
    • 2.1.1 Roche Holding AG Details
    • 2.1.2 Roche Holding AG Major Business
    • 2.1.3 Roche Holding AG Pleurodynia Treatment Product and Services
    • 2.1.4 Roche Holding AG Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Holding AG Recent Developments/Updates
  • 2.2 Gilead Sciences
    • 2.2.1 Gilead Sciences Details
    • 2.2.2 Gilead Sciences Major Business
    • 2.2.3 Gilead Sciences Pleurodynia Treatment Product and Services
    • 2.2.4 Gilead Sciences Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Gilead Sciences Recent Developments/Updates
  • 2.3 AbbVie
    • 2.3.1 AbbVie Details
    • 2.3.2 AbbVie Major Business
    • 2.3.3 AbbVie Pleurodynia Treatment Product and Services
    • 2.3.4 AbbVie Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 AbbVie Recent Developments/Updates
  • 2.4 GlaxoSmithKline
    • 2.4.1 GlaxoSmithKline Details
    • 2.4.2 GlaxoSmithKline Major Business
    • 2.4.3 GlaxoSmithKline Pleurodynia Treatment Product and Services
    • 2.4.4 GlaxoSmithKline Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 GlaxoSmithKline Recent Developments/Updates
  • 2.5 Bristol Myers Squibb
    • 2.5.1 Bristol Myers Squibb Details
    • 2.5.2 Bristol Myers Squibb Major Business
    • 2.5.3 Bristol Myers Squibb Pleurodynia Treatment Product and Services
    • 2.5.4 Bristol Myers Squibb Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Bristol Myers Squibb Recent Developments/Updates
  • 2.6 Johnson & Johnson
    • 2.6.1 Johnson & Johnson Details
    • 2.6.2 Johnson & Johnson Major Business
    • 2.6.3 Johnson & Johnson Pleurodynia Treatment Product and Services
    • 2.6.4 Johnson & Johnson Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Johnson & Johnson Recent Developments/Updates
  • 2.7 Boehringer Ingelheim
    • 2.7.1 Boehringer Ingelheim Details
    • 2.7.2 Boehringer Ingelheim Major Business
    • 2.7.3 Boehringer Ingelheim Pleurodynia Treatment Product and Services
    • 2.7.4 Boehringer Ingelheim Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Boehringer Ingelheim Recent Developments/Updates
  • 2.8 Pfizer
    • 2.8.1 Pfizer Details
    • 2.8.2 Pfizer Major Business
    • 2.8.3 Pfizer Pleurodynia Treatment Product and Services
    • 2.8.4 Pfizer Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Pfizer Recent Developments/Updates
  • 2.9 Novartis
    • 2.9.1 Novartis Details
    • 2.9.2 Novartis Major Business
    • 2.9.3 Novartis Pleurodynia Treatment Product and Services
    • 2.9.4 Novartis Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Novartis Recent Developments/Updates
  • 2.10 Takeda Pharmaceuticals
    • 2.10.1 Takeda Pharmaceuticals Details
    • 2.10.2 Takeda Pharmaceuticals Major Business
    • 2.10.3 Takeda Pharmaceuticals Pleurodynia Treatment Product and Services
    • 2.10.4 Takeda Pharmaceuticals Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Takeda Pharmaceuticals Recent Developments/Updates
  • 2.11 Merck & Co.
    • 2.11.1 Merck & Co. Details
    • 2.11.2 Merck & Co. Major Business
    • 2.11.3 Merck & Co. Pleurodynia Treatment Product and Services
    • 2.11.4 Merck & Co. Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Merck & Co. Recent Developments/Updates
  • 2.12 Bayer
    • 2.12.1 Bayer Details
    • 2.12.2 Bayer Major Business
    • 2.12.3 Bayer Pleurodynia Treatment Product and Services
    • 2.12.4 Bayer Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Bayer Recent Developments/Updates
  • 2.13 Teva Pharmaceutical lndustries
    • 2.13.1 Teva Pharmaceutical lndustries Details
    • 2.13.2 Teva Pharmaceutical lndustries Major Business
    • 2.13.3 Teva Pharmaceutical lndustries Pleurodynia Treatment Product and Services
    • 2.13.4 Teva Pharmaceutical lndustries Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Teva Pharmaceutical lndustries Recent Developments/Updates
  • 2.14 AstraZeneca
    • 2.14.1 AstraZeneca Details
    • 2.14.2 AstraZeneca Major Business
    • 2.14.3 AstraZeneca Pleurodynia Treatment Product and Services
    • 2.14.4 AstraZeneca Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 AstraZeneca Recent Developments/Updates
  • 2.15 Amgen
    • 2.15.1 Amgen Details
    • 2.15.2 Amgen Major Business
    • 2.15.3 Amgen Pleurodynia Treatment Product and Services
    • 2.15.4 Amgen Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Amgen Recent Developments/Updates
  • 2.16 Eli Lilly and Company
    • 2.16.1 Eli Lilly and Company Details
    • 2.16.2 Eli Lilly and Company Major Business
    • 2.16.3 Eli Lilly and Company Pleurodynia Treatment Product and Services
    • 2.16.4 Eli Lilly and Company Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Eli Lilly and Company Recent Developments/Updates
  • 2.17 Sanofi
    • 2.17.1 Sanofi Details
    • 2.17.2 Sanofi Major Business
    • 2.17.3 Sanofi Pleurodynia Treatment Product and Services
    • 2.17.4 Sanofi Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Sanofi Recent Developments/Updates
  • 2.18 Daiichi Sankyo
    • 2.18.1 Daiichi Sankyo Details
    • 2.18.2 Daiichi Sankyo Major Business
    • 2.18.3 Daiichi Sankyo Pleurodynia Treatment Product and Services
    • 2.18.4 Daiichi Sankyo Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Daiichi Sankyo Recent Developments/Updates
  • 2.19 Astellas Pharma.
    • 2.19.1 Astellas Pharma. Details
    • 2.19.2 Astellas Pharma. Major Business
    • 2.19.3 Astellas Pharma. Pleurodynia Treatment Product and Services
    • 2.19.4 Astellas Pharma. Pleurodynia Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Astellas Pharma. Recent Developments/Updates

3 Competitive Environment: Pleurodynia Treatment by Manufacturer

  • 3.1 Global Pleurodynia Treatment Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Pleurodynia Treatment Revenue by Manufacturer (2021-2026)
  • 3.3 Global Pleurodynia Treatment Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Pleurodynia Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Pleurodynia Treatment Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Pleurodynia Treatment Manufacturer Market Share in 2025
  • 3.5 Pleurodynia Treatment Market: Overall Company Footprint Analysis
    • 3.5.1 Pleurodynia Treatment Market: Region Footprint
    • 3.5.2 Pleurodynia Treatment Market: Company Product Type Footprint
    • 3.5.3 Pleurodynia Treatment Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Pleurodynia Treatment Market Size by Region
    • 4.1.1 Global Pleurodynia Treatment Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Pleurodynia Treatment Consumption Value by Region (2021-2032)
    • 4.1.3 Global Pleurodynia Treatment Average Price by Region (2021-2032)
  • 4.2 North America Pleurodynia Treatment Consumption Value (2021-2032)
  • 4.3 Europe Pleurodynia Treatment Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Pleurodynia Treatment Consumption Value (2021-2032)
  • 4.5 South America Pleurodynia Treatment Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Pleurodynia Treatment Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Pleurodynia Treatment Sales Quantity by Type (2021-2032)
  • 5.2 Global Pleurodynia Treatment Consumption Value by Type (2021-2032)
  • 5.3 Global Pleurodynia Treatment Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Pleurodynia Treatment Sales Quantity by Application (2021-2032)
  • 6.2 Global Pleurodynia Treatment Consumption Value by Application (2021-2032)
  • 6.3 Global Pleurodynia Treatment Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Pleurodynia Treatment Sales Quantity by Type (2021-2032)
  • 7.2 North America Pleurodynia Treatment Sales Quantity by Application (2021-2032)
  • 7.3 North America Pleurodynia Treatment Market Size by Country
    • 7.3.1 North America Pleurodynia Treatment Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Pleurodynia Treatment Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Pleurodynia Treatment Sales Quantity by Type (2021-2032)
  • 8.2 Europe Pleurodynia Treatment Sales Quantity by Application (2021-2032)
  • 8.3 Europe Pleurodynia Treatment Market Size by Country
    • 8.3.1 Europe Pleurodynia Treatment Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Pleurodynia Treatment Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Pleurodynia Treatment Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Pleurodynia Treatment Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Pleurodynia Treatment Market Size by Region
    • 9.3.1 Asia-Pacific Pleurodynia Treatment Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Pleurodynia Treatment Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Pleurodynia Treatment Sales Quantity by Type (2021-2032)
  • 10.2 South America Pleurodynia Treatment Sales Quantity by Application (2021-2032)
  • 10.3 South America Pleurodynia Treatment Market Size by Country
    • 10.3.1 South America Pleurodynia Treatment Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Pleurodynia Treatment Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Pleurodynia Treatment Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Pleurodynia Treatment Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Pleurodynia Treatment Market Size by Country
    • 11.3.1 Middle East & Africa Pleurodynia Treatment Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Pleurodynia Treatment Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Pleurodynia Treatment Market Drivers
  • 12.2 Pleurodynia Treatment Market Restraints
  • 12.3 Pleurodynia Treatment Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Pleurodynia Treatment and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Pleurodynia Treatment
  • 13.3 Pleurodynia Treatment Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Pleurodynia Treatment Typical Distributors
  • 14.3 Pleurodynia Treatment Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Pleurodynia Treatment market size was valued at US$ 150 million in 2025 and is forecast to a readjusted size of US$ 217 million by 2032 with a CAGR of 5.5% during review period.
    Pleurodynia is also known as Bornholm disease and is categorized by the occurrence of sudden and severe abdominal and chest pain. Currently, the disease does not have any specific treatment plan that can effectively treat the condition from the root. The existing standard of care requires symptom management and pain relief treatment with suggestions for resting.
    The global pleuritic pain treatment market is expected to witness high growth owing to rising cases of pleuritic pain globally. This has led to an increased need for effective treatments and medicines. However, the industry currently only offers pain and symptom management therapies or medications, and there is no accurate cure for the condition.
    This report is a detailed and comprehensive analysis for global Pleurodynia Treatment market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Pleurodynia Treatment market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Pleurodynia Treatment market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Pleurodynia Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Pleurodynia Treatment market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Pleurodynia Treatment
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Pleurodynia Treatment market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche Holding AG, Gilead Sciences, AbbVie, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Boehringer Ingelheim, Pfizer, Novartis, Takeda Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Pleurodynia Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Anti-Inflammatory Drugs
    Analgesics
    Other
    Market segment by Application
    Hospital
    Clinic
    Other
    Major players covered
    Roche Holding AG
    Gilead Sciences
    AbbVie
    GlaxoSmithKline
    Bristol Myers Squibb
    Johnson & Johnson
    Boehringer Ingelheim
    Pfizer
    Novartis
    Takeda Pharmaceuticals
    Merck & Co.
    Bayer
    Teva Pharmaceutical lndustries
    AstraZeneca
    Amgen
    Eli Lilly and Company
    Sanofi
    Daiichi Sankyo
    Astellas Pharma.
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Pleurodynia Treatment product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Pleurodynia Treatment, with price, sales quantity, revenue, and global market share of Pleurodynia Treatment from 2021 to 2026.
    Chapter 3, the Pleurodynia Treatment competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Pleurodynia Treatment breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pleurodynia Treatment market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Pleurodynia Treatment.
    Chapter 14 and 15, to describe Pleurodynia Treatment sales channel, distributors, customers, research findings and conclusion.

    Buy now